Referred to the House Committee on Veterans' Affairs.

Original title: “HR 9872: To designate the community-based outpatient clinic of the Department of Veterans Affairs in Saint Croix, United States Virgin Islands, as the "Lieutenant Colonel David C. Canegata III Department of Veterans Affairs Community-Based Outpatient Clinic".”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9867: Expand the Behavioral Health Workforce Now Act”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 3122: Better FDA Act of 2025”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9488: Health Disparity Zones Act of 2026”

The Food and Drug Administration (FDA or Agency) is announcing the publication of FDA's Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development (Strategy Document), which outlines actions FDA has taken and the Agency's plans for fiscal years 2026-2027 to facilitate chemistry, manufacturing, and controls (CMC) readiness for products with accelerated clinical development timelines. As part of the Prescription Drug User F

Original title: “FDA's Strategy Document on Facilitating Chemistry, Manufacturing, and Controls Readiness for Products With Accelerated Clinical Development”

The U.S. Department of Health and Human Services (HHS or the Department) rescinds the Guidelines for Eliminating Discrimination and Denial of Services on the Basis of Race, Color, National Origin, Sex, and Handicap in Vocational Education Programs (Guidelines). The Department also makes conforming amendments by removing cross- references to the Guidelines in its regulations. The Guidelines were developed and issued by HHS's predecessor, the Department of Health, Education, and Welfare (HEW), in

Original title: “Rescinding Guidelines for Eliminating Discrimination and Denial of Services on the Basis of Race, Color, National Origin, Sex, and Handicap in Vocational Education Programs”

Read twice and referred to the Committee on Finance.

Original title: “S 5120: Increasing Mental Health Options Act of 2026”

The Food and Drug Administration (FDA or we) is proposing to issue an order that would repeal the color additive regulation that allows for the use of Citrus Red No. 2 for coloring the skins of mature oranges. Based on certification data, it appears that Citrus Red No. 2 is no longer used for coloring the skins of oranges and has not been certified for use as a color additive in food marketed in the United States since 2020. Because the authorized use of Citrus Red No. 2 appears to have been aba

Original title: “Proposal To Revoke the Color Additive Listing for Use of Citrus Red No. 2 on the Skins of Mature Oranges”

In accordance with Title II of the Foundations for Evidence- Based Policymaking Act of 2018, known as the Open, Public, Electronic, and Necessary (OPEN) Government Data Act, CMS announces the forthcoming release of public data assets in open, machine-readable formats under an open license. These data are intended to support public engagement in identifying and preventing fraud, waste, and abuse, and to promote transparency and accountability. CMS has taken steps to ensure that the release of the

Original title: “Notice of Public Data Asset Release Under the Open, Public, Electronic, and Necessary (OPEN) Government Data Act”

The Food and Drug Administration (FDA or we) is issuing an order to repeal the color additive regulation that allows for the use of Orange B for coloring the casings or surfaces of frankfurters and sausages. We have determined that the authorized use of Orange B has been abandoned, and we have concluded that this color additive regulation is outdated and unnecessary. Therefore, FDA is revoking the authorized use in food of Orange B in the color additive regulations.

Original title: “Revocation of the Color Additive Listing for Use of Orange B on Casings or Surfaces of Frankfurters and Sausages”

The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervo

Original title: “Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment”

On May 5, 2026, the Agency for Toxic Substances and Disease Registry (ATSDR), within the Department of Health and Human Services (HHS), announced the opening of a docket to obtain comments on the draft toxicological profile for xylene. This notice extends the comment period to September 2, 2026.

Original title: “Availability of Draft Toxicological Profile for Xylene; Extension of Comment Period”

This notice announces the public meeting of the Advisory Council on Alzheimer's Research, Care, and Services (Advisory Council). The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias on people living with the disease and their caregivers. During the third meeting of 2026, the Advisory Council will hear from a panel organized by the research subcommittee; updates from federal agencies, including an overview of the authorities of t

Original title: “Advisory Council on Alzheimer's Research, Care, and Services; Meeting”

Read twice and referred to the Committee on Finance.

Original title: “S 1936: Improving Access to Transfusion Care for Hospice Patients Act of 2025”

Referred to the House Committee on Ways and Means.

Original title: “HR 9703: Improving Access to Transfusion Care for Hospice Patients Act of 2026”

The second half of 2026 is well under way, signaling a shift in focus for state policy activities as the majority of states have now completed their legislative activity for […]

Original title: “A Mid-Year State Policy Recap”

While the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove more disruptive.

Original title: “Trump threatens tariffs on imported generic drugs”